DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 …

DFX117 2125500-60-7 DFX 117 DFX-117 PI3K Akt mTOR Apoptosis Phosphoinositide 3-kinase PKB Protein kinase B Mammalian target of Rapamycin NCI-H1975 NCI-H1993 HCC827 …

The antitumor activity and underlying mechanisms of DFX117 against non-small cell lung cancer (NSCLC) cells were evaluated in both in vitro and in vivo animal models and highlight the …

2019年5月5日 · Herein, the antitumor activity and underlying mechanisms of DFX117 against non-small cell lung cancer (NSCLC) cells were evaluated in both in vitro and in vivo animal …

DFX-117|DFX 117: Drug Descriptions: DFX117 is a dual inhibitor that blocks Met and selectively inhibits Pik3ca kinase activity, which potentially results in inhibition of cell proliferation, and …

Deferasirox (DFX) and deferoxamine (DFO) are among the most common iron chelation agents available in the clinical setting. The aim of this study was to investigate if the combination …

DFX117 significantly induces growth inhibition of non-small cell lung cancer cells. (A) The proliferation of four lung cancer cell lines (A549, NCI-H1975, PC9 and NCI-H1993) were …

Cancers 2019, 11, 627 2 of 20 resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) [5–7]. There is an increasing number of evidence that show that the c …

DFX117 Cat. No.: HY-164384 CAS No.: 2125500-60-7 Molecular Formula: C26H26F2N6O5S Molecular Weight: 572.58 Target: PI3K; Akt; mTOR; Apoptosis Pathway: PI3K/Akt/mTOR ...